CANbridge Pharmaceuticals Inc. (the Group) issued a supplemental announcement regarding the grant of Share Options and Restricted Share Units (RSUs) originally disclosed in the announcement dated January 12, 2026. The update clarifies details about two external service providers who support the Group’s research and development strategy and regulatory approval processes.

The two service providers, identified as Service Provider 1 and Service Provider 2, offer long-term development strategy advice and regulatory consulting support, respectively. According to the Board, granting Share Options and RSUs aligns with the purpose of the schemes by reflecting the continuing and recurring nature of these services, as well as their importance to the Group’s business, growth, and development. No further supplementary information was provided beyond these clarifications.